Colon-26

Zellname

Beschreibung

Bestell-Nr.

Einheit

Preis, Euro

Colon-26

Murine Kolonkarzinom Zell-Linie

400156

cryovial

375,00

Colon-26

Murine Kolonkarzinom Zell-Linie

440156

vital

465,00



Designation:Colon-26
Depositor:CLS; Mason Research Institute
Organism:Mus musculus (mouse)
Strain:Balb/C
Gender:female
Tissue:colon
Morphology:epithelial
Celltype:epithelial
Growth Properties:monolayer
Description:Established ‘in vitro’ from the colon-26 tumor of female mice. This tumor was induced in Balb/c mice by single rectal application of N-Nitroso-N-Methylurethan (NMU).
Culture Medium:RPMI 1640 media supplemented with 2 mM L-glutamine and 10% fetal bovine serum - or - DMEM 4.5 g/L glucose supplemented with 2 mM L-glutamine and 10% fetal bovine serum.
Subculturing:Remove media and rinse with 0.02% EDTA solution. Add fresh 0.025% trypsin for 2 to 3 minutes, remove trypsin and let the culture sit at room temperature until the cells detach. Add fresh media, collect the cells and dispense into new flasks.
Split Ratio:A ratio of 1:4 to 1:6 is recommended
Fluid Renewal:2 to 3 times weekly
Freeze Medium:CM-1 (CLS · Cell Lines Service)
Sterility:Tests for mycoplasma, bacteria and fungi were negative
Biosafety Level:1
Tumorigenic:in Balb/c mice
Receptors Expressed:interleukin 2 (IL-2)
Viruses:MAP-TEST negative: Sendai, Ektromelia, Polyoma, K-Virus, Kilham, Reo 3, PVM, LCM, M.pulmonis, MVM, Theiler's GD VII, Toolan's H-1, MHV, LDV, RCV/SDA, M-Adenovirus, B.piliformis.


References:

Alison DC, Ridolpho PF, Anderson S, Bose K. Variations in the [3H]thymidine labeling of S-phase cells in solid mouse tumors. Cancer Res 45: 6010-6, 1985. Bodenner DL, Dedon PC, Keng PC, Katz JC, Borch RF. Selective protection against cis-diaminedichloroplatinum(II)-induced toxicity in kidney, gut, and bone marrow by diethyldithiocarbamante. Cancer Res 46: 2751-5, 1986. Bernacki RJ, Bansal SK, Gurtoo HL. Combinations of mesna with cyclophophamide or adriamycin in the treatment of mice with tumors. Cancer Res 47(3): 799-802, 1987. Nukatsuka M, Fujioka A, Saito H, Uchida J, Nakano K, Takeda S, Unemi N. Prolongation of survival period and improvement of cancer cachexia by long-term administration of UFT. Cancer Lett 104(2): 197-203, 1996. Seed MP, Brown JR, Freemantle CN, Papworth JL, Colville-Nash PR, Willis D, Somerville KW, Asculai S, Wiloughby DA. The inhibition of colon-26 adenocarcinoma development and angiogenesis by topical diclofenac in 2.5% hyaluronan. Cancer Res 57(9):1625-9, 1997. Ishida H, Hashimoto D, Takeuchi I, Yokoyama M, Okita T, Hoshino T. Liver metastases are less established after gasless laparoscopy than after carbon dioxide pneumoperitoneum and laparotomy in a mouse model. Surg Endosc. 16(1):193-6, 2002. Ishida H, Hashimoto D, Nakada H, Takeuchi I, Hoshino T, Murata N, Idezuki Y, Hosono M. Increased insufflation pressure enhances the development of liver metastasis in a mouse laparoscopy model: possible mechanisms. Surg Endosc. 16(2):331-5, 2002. Mizoue T, Horibe T, Maruyama K, Takizawa T, Iwatsuru M, Kono K, Yanagie H, Moriyasu F. Targetability and intracellular delivery of anti-BCG antibody-modified, pH-sensitive fusogenic immunoliposomes to tumor cells. Int J Pharm. 237(1-2):129-37, 2002. Nishikawa M, Tamada A, Kumai H, Yamashita F, Hashida M. Inhibition of experimental pulmonary metastasis by controlling biodistribution of catalase in mice. Int J Cancer. 99(3):474-9, 2002. Iizuka N, Hazama S, Yoshimura K, Yoshino S, Tangoku A, Miyamoto K, Okita K, Oka M. Anticachectic effects of the natural herb Coptidis rhizoma and berberine on mice bearing colon 26/clone 20 adenocarcinoma. Int J Cancer. 99(2):286-91, 2002. Sugahara S, Kajiki M, Kuriyama H, Kobayashi TR. Paclitaxel delivery systems: the use of amino acid linkers in the conjugation of paclitaxel with carboxymethyldextran to create prodrugs. Biol Pharm Bull. 25(5):632-41, 2002. Usia T, Banskota AH, Tezuka Y, Midorikawa K, Matsushige K, Kadota S. Constituents of Chinese propolis and their antiproliferative activities. J Nat Prod. 65(5):673-6, 2002. Tilignac T, Temparis S, Combaret L, Taillandier D, Pouch MN, Cervek M, Cardenas DM, Le Bricon T, Debiton E, Samuels SE, Madelmont JC, Attaix D. Chemotherapy inhibits skeletal muscle ubiquitin-proteasome-dependent proteolysis. Cancer Res. 62(10):2771-7, 2002. Golab J, Olszewska D, Mroz P, Kozar K, Kaminski R, Jalili A, Jakobisiak M. Erythropoietin Restores the Antitumor Effectiveness of Photodynamic Therapy in Mice with Chemotherapy- induced Anemia. Clin Cancer Res. 8(5):1265-70, 2002. Gunji Y, Yol S, Suzuki T, Hori S, Hayashi H, Shimada H, Matsubara H, Nabeya Y, Ochiai T. Analysis of experimental liver metastasis from tumors inoculated in the mouse stomach cavity. Surg Today 32(2):142-7, 2002. Codacci-Pisanelli G, Van der Wilt CL, Smid K, Noordhuis P, Voorn D, Pinedo HM, Peters GJ. High-dose 5-Fluorouracil with uridine-diphosphoglucose rescue increases thymidylate synthase inhibition but not 5-Fluorouracil incorporation into RNA in murine tumors. Oncology 62(4):363-70, 2002. Ueda JY, Tezuka Y, Banskota AH, Le Tran Q, Tran QK, Harimaya Y, Saiki I, Kadota S. Antiproliferative activity of Vietnamese medicinal plants. Biol Pharm Bull. 25(6):753-60, 2002. Feleszko W, Jalili A, Olszewska D, Mlynarczuk I, Grzela T, Giermasz A, Jakobisiak M. Synergistic interaction between highly specific cyclooxygenase-2 inhibitor, MF-tricyclic and lovastatin in murine colorectal cancer cell lines. Oncol Rep. 9(4):879-85, 2002. Lee CW, Hong DH, Han SB, Jung SH, Kim HC, Fine RL, Lee SH, Kim HM. A novel stereo-selective sulfonylurea, 1-[1-(4-aminobenzoyl)-2,3-dihydro-1H-indol-6-sulfonyl]-4-phenyl-imidazolidin-2-one, has antitumor efficacy in in vitro and in vivo tumor models. Biochem Pharmacol. 64(3):473-80, 2002. Nagaoka T, Banskota AH, Tezuka Y, Saiki I, Kadota S. Selective antiproliferative activity of caffeic acid phenethyl ester analogues on highly liver-Metastatic murine colon 26-L5 carcinoma cell line. Bioorg Med Chem. 10(10):3351-3359, 2002.

 

  Change language: eng        Diese Seite drucken   Sitemap   Kontakt  
Ihre Ansprechpartner
Gerne beantworten wir Ihre Fragen rund um unsere Zell-Linien und weitere Produkte.
Tel.: +49 (0)6221 700799
Fax.: +49 (0)6221 700717
Zertifikat
Zertifikat
CLS Cell Lines Service ist nach ISO9001:2008 zertifiziert.


 
top